Midwife Licensure Exam High-Risk Pregnancy & Complications (Recognize & Refer) — High-Risk Pregnancy & Bleeding DisordersStudy Notes

First-trimester bleeding occurs before 13 weeks of gestation and accounts for approximately 20% of all pregnancies. The most common cause is spontaneous abortion (miscarriage), followed by ectopic pregnancy and gestational trophoblastic disease. From a nursing perspective, first-trimester bleeding requires careful assessment to differentiate between a viable pregnancy continuation and a nonviable pregnancy that requires intervention. The key clinical decision point is determining whether the pregnancy can be salvaged (threatened abortion) or if evacuation of the uterus is necessary (inevitable, incomplete, or complete abortion). Understanding the types of abortion is critical for NLE success and clinical practice. Each type has distinct characteristics, prognoses, and nursing interventions. **Types of Spontaneous Abortion:** 1. **Threatened Abortion**: The cervical os remains closed despite vaginal bleeding and mild cramping before 20 weeks. Approximately 50% of threatened abortions progress to term; the other 50% progress to inevitable abortion. The bleeding is scant to moderate, and the uterus is appropriately sized for dates. There is no passage of tissue or fetal parts. 2. **Inevitable Abortion**: The cervical os becomes dilated, indicating that pregnancy loss cannot be stopped. Bleeding is moderate to heavy, cramping intensifies, and membranes may rupture. The uterus may feel slightly smaller than expected. This progresses to either complete or incomplete abortion within hours to days. 3. **Incomplete Abortion**: Some products of conception are expelled through the open cervical os, but some retain in the uterine cavity. This is a partially evacuated uterus. Heavy bleeding and severe cramping persist because the uterus contracts around retained tissue, creating a physiologic mechanism for hemorrhage. The cervix remains dilated. This is a high-risk state for infection and ongoing bleeding and typically requires urgent dilation and curettage (D&C) or suction evacuation. 4. **Complete Abortion**: All products of conception have been expelled naturally. The cervix gradually closes. Bleeding and cramping diminish significantly or cease. The uterus is small and firm (well-contracted). The history often shows passage of tissue, fetal parts, or placental material. No intervention is required beyond supportive care and Rho(D) immune globulin for eligible women. 5. **Missed Abortion**: The fetus dies in utero, but the products of conception are retained. Clinically, bleeding may be absent initially; the uterus may feel smaller than expected for dates; and beta-hCG levels may plateau or decline. This diagnosis is typically confirmed by ultrasound showing no fetal cardiac activity. The critical danger is that if a missed abortion is retained beyond 4–6 weeks, thromboplastin from the degenerating fetal tissue can enter the maternal circulation, triggering disseminated intravascular coagulation (DIC)—a consumptive coagulopathy that causes life-threatening hemorrhage and organ failure. Timely evacuation prevents this complication. 6. **Recurrent (Habitual) Abortion**: Three or more consecutive spontaneous abortions define recurrent abortion. Causes include chromosomal abnormalities in the parents, maternal antiphospholipid antibody syndrome, thyroid disease, uterine structural defects (septate uterus, uterine fibroids), incompetent cervix, and immunologic factors. Management involves investigation of the cause and, if an incompetent cervix is identified, cerclage (surgical cervical reinforcement) may be placed between 12–16 weeks in the next pregnancy. **Pathophysiology of Spontaneous Abortion:** The leading cause of first-trimester abortion is chromosomal abnormality in the fetus (approximately 50–60% of cases), reflecting the natural selection process. Other causes include maternal infection (cytomegalovirus, rubella, toxoplasmosis), endocrine imbalance (hypothyroidism, diabetes mellitus with poor control, progesterone deficiency), structural uterine defects, trauma, severe maternal systemic disease, and immunologic rejection of the embryo (particularly antiphospholipid antibody syndrome).

Systematic assessment of first-trimester bleeding is essential for safe nursing care. The nurse's role—informed by the nursing process and NANDA-I framework—is to gather comprehensive data, recognize the type of abortion, identify the risk for complications, and implement evidence-based interventions. **Assessment Framework:** **A. History & Symptoms:** - Last menstrual period (LMP) and estimated date of confinement (EDC) - Onset, duration, and character of bleeding (spotting vs. heavy flow) - Associated pain: location, severity, character (cramping vs. sharp), and radiation - Passage of tissue, clots, or fetal parts (save ALL tissue for evaluation) - Recent trauma, sexual intercourse, or vaginal procedures - History of prior miscarriages, ectopic pregnancy, or uterine procedures - Systemic symptoms: fever (suggests infection), syncope (suggests hemorrhage) **B. Vital Signs & Hemodynamic Assessment:** - Blood pressure, heart rate, respiratory rate, temperature - Signs of hypovolemic shock: tachycardia (>100 bpm), hypotension (a LATE sign), narrowing pulse pressure, cool and clammy skin, restlessness, anxiety, confusion - Orthostatic vital signs if hemorrhage is suspected **C. Abdominal & Pelvic Examination:** - Abdominal tenderness, distension, guarding, or rigidity (suggests intra-abdominal bleeding or rupture) - Speculum exam: visualize bleeding source, assess cervical dilation, look for passage of tissue - Gentle bimanual exam (only after speculum visualization): uterine size relative to dates, uterine tenderness, adnexal masses (suggests ectopic pregnancy) - **Never perform a digital cervical exam until ectopic pregnancy is ruled out**—a cervical manipulation could rupture an unsuspected ectopic pregnancy **D. Quantification of Blood Loss:** - Count and weigh perineal pads: 1 gram weight = 1 mL blood loss (this is crucial for documentation) - Note color (bright red vs. dark), clots (>2 cm suggests significant bleeding), and tissue passage - Record estimated blood loss (EBL) every 1–2 hours during active bleeding **E. Diagnostic Testing:** - **Serum beta-hCG (quantitative)**: should double every 48–72 hours in early viable pregnancy; slower rise or plateau suggests nonviable pregnancy - **Hemoglobin/hematocrit**: baseline and serially if bleeding is ongoing - **Blood type and antibody screen**: prepare for potential transfusion - **Ultrasound (transvaginal preferred)**: confirms intrauterine pregnancy, detects fetal cardiac activity, rules out ectopic pregnancy, assesses for retained products - **Rh status**: determine need for Rho(D) immune globulin **Nursing Diagnoses (NANDA-I Framework):** 1. **Deficient Fluid Volume** related to vaginal bleeding as evidenced by tachycardia, hypotension, or decreased urine output (Maslow Level 2: Physiologic Safety) 2. **Risk for Infection** related to open cervix and potential for bacterial ascension (Maslow Level 2: Safety) 3. **Acute Pain** related to uterine cramping and contractions as evidenced by verbal reports, guarding, facial grimacing (Maslow Level 2: Physiologic Safety) 4. **Grieving** related to loss of pregnancy as evidenced by crying, sadness, expressions of loss (Maslow Level 3: Love & Belonging / Level 4: Esteem) 5. **Fear** related to threat to health status and uncertainty about outcome as evidenced by verbalization of worry, restlessness (Maslow Level 2: Safety) **Priority Nursing Interventions:** **1. Monitor & Maintain Hemodynamic Stability (Maslow Level 2):** - Establish two large-bore IV lines (18-gauge or larger) if bleeding is moderate to heavy - Initiate normal saline (0.9% NaCl) or lactated Ringer's solution at rapid infusion rates if hemorrhage is suspected - Monitor vital signs every 15–30 minutes during active bleeding; every 1–2 hours if stable - Maintain continuous pulse oximetry; target SpO2 ≥95% - Administer supplemental oxygen via nasal cannula 2–3 L/min if signs of hemorrhagic shock appear - Measure urine output hourly; target >30 mL/hr; oliguria (urine output <30 mL/hr or <0.5 mL/kg/hr) signals inadequate perfusion - Place patient on continuous fetal monitoring if fetal viability is suspected - Prepare for blood transfusion (packed red blood cells, fresh frozen plasma, platelets) if hemorrhage is severe **2. Prevent Infection (Maslow Level 2):** - Reinforce aseptic technique during examination and any procedures - Advise against douching, tampons, and intercourse until after bleeding cessation - Teach signs of infection to report: fever, foul-smelling vaginal discharge, severe pain, or chills - If D&C is performed, administer prophylactic antibiotics per protocol (e.g., doxycycline or amoxicillin) **3. Manage Pain (Maslow Level 2):** - Assess pain intensity (0–10 scale) and character; differentiate uterine cramping from sharp abdominal or shoulder pain (latter may indicate ectopic pregnancy or rupture) - Administer analgesia as prescribed: acetaminophen 650–1,000 mg PO every 4–6 hours, or ibuprofen 400–600 mg PO every 6–8 hours - Position for comfort; offer heating pad to lower abdomen (if no contraindications) - Teach relaxation and breathing techniques - Notify provider if pain is sudden, severe, one-sided, or associated with shoulder pain **4. Provide Grief Support & Psychological Care (Maslow Levels 3 & 4):** - Acknowledge the loss without minimizing it; avoid clichés such as "you can have another baby" or "it was for the best" - Use empathic listening; allow verbalization of feelings - Offer the opportunity to see, hold, or have a picture of the fetus if the parents wish (especially after 10–12 weeks) - Provide grief literature and referrals to support groups or counseling services - Document the parents' wishes regarding fetal remains and baptism (if applicable) - Coordinate with the chaplain or social worker if spiritual support is needed - Follow up with the family after discharge; postpartum grief can persist for months **5. Prepare for Possible Surgical Intervention:** - If abortion is inevitable or incomplete, prepare for D&C or suction evacuation under anesthesia - Provide preoperative teaching: NPO status, expected sensations, postoperative recovery - Ensure informed consent is obtained and documented - Send any passed tissue for pathologic examination **6. Administer Rho(D) Immune Globulin (for Rh-Negative, Unsensitized Women):** - Verify Rh status and indirect Coombs (should be negative, meaning not already sensitized) - Give **50 mcg microdose** for first-trimester abortion (under 13 weeks) - Administer IM into deltoid or gluteus maximus (never IV) - Document lot number and expiration date - Counsel patient: this injection protects future pregnancies from hemolytic disease **Discharge Teaching:** - Rest and gradual return to normal activities; avoid heavy lifting and strenuous exercise for 1–2 weeks - Avoid intercourse, douching, and tampons until bleeding has completely stopped and cleared by provider - Expect some spotting or light bleeding for up to 2 weeks post-abortion - Take prescribed antibiotics (if given) and pain medication as directed - Return to the clinic in 2 weeks for follow-up examination and confirmation of complete evacuation - Notify provider immediately if fever >38.5°C, heavy or prolonged bleeding, foul-smelling discharge, or severe pain develops - **Emotional support**: grief is normal; counseling and support groups are available - Discuss future pregnancy planning; most providers recommend waiting 1–2 menstrual cycles before attempting pregnancy again to allow uterine recovery and psychological adjustment

An ectopic pregnancy occurs when the fertilized ovum implants and develops outside the uterine cavity. Over 95% of ectopic pregnancies occur in the fallopian tube; the remainder implant in the ovary, peritoneal cavity, or cervix. Ectopic pregnancy is a potentially life-threatening obstetric emergency that kills more women than any other first-trimester complication. The challenge for nurses is recognizing the early (unruptured) phase when medical management with methotrexate can salvage the patient's fertility, versus the ruptured phase, which demands immediate surgical intervention to prevent death from hemorrhagic shock. **Epidemiology & Risk Factors:** Risk factors for ectopic pregnancy include pelvic inflammatory disease (PID) from sexually transmitted infections, prior tubal surgery (especially tubal ligation reversal), previous ectopic pregnancy (recurrence rate ~25% if untreated), intrauterine device (IUD) use, endometriosis, and congenital tubal anomalies. Any condition that impairs tubal motility or patency increases risk. **Pathophysiology:** The fallopian tube is a muscular conduit, not designed for pregnancy. As the embryo grows, it erodes the tubal wall, eventually causing tubal rupture and catastrophic intra-abdominal hemorrhage. Rupture typically occurs between 6–16 weeks of gestation, most often around 8–12 weeks. **Clinical Presentation: The Classic NLE Triad:** **1. Unilateral Lower-Quadrant Abdominal Pain:** This is the most consistent symptom. Pain may be mild and localized to one side initially, then become severe and generalized if rupture occurs. The pain reflects the stretching of the tubal wall and, if ruptured, irritation of the peritoneum by blood and trophoblastic tissue. **2. Abnormal Vaginal Bleeding:** Bleeding is often scant and dark ("prune juice" color), distinguishing it from normal menstruation or threatened abortion. The bleeding reflects decidual shedding from the endometrium as it responds to hormonal withdrawal when the ectopic trophoblast fails to produce adequate progesterone. **3. Signs of Hypovolemic Shock (if ruptured):** Rupture is a surgical emergency. Sudden, sharp stabbing pain occurs as the tube tears. Referred **shoulder pain (Kehr sign)** is a pathognomonic sign—it results from irritation of the diaphragm by blood in the peritoneal cavity. The bleeding is rapid and massive (a ruptured tubal artery can bleed 1–2 liters in minutes). Tachycardia (>110 bpm), hypotension (BP <90/60 mmHg), pallor, cool clammy skin, syncope, and mental confusion follow. **Cullen sign** (bluish periumbilical discoloration) may appear if intra-abdominal bleeding tracks around the umbilicus. **Clinical Distinction: Unruptured vs. Ruptured Ectopic Pregnancy** | Feature | Unruptured | Ruptured | |---------|-----------|----------| | Pain | Mild to moderate, unilateral | Sudden severe stabbing pain | | Shoulder pain | Absent | Present (Kehr sign) | | Vital signs | Stable or mild tachycardia | Severe tachycardia, hypotension | | Abdominal exam | Mild tenderness, possibly palpable mass | Board-like rigidity, severe guarding | | Cullen sign | Absent | May be present | | Hemoglobin | Mild decrease or normal | Significant drop (>2 g/dL) | | Outcome | Medical (methotrexate) or conservative management possible | Emergency surgery mandatory | **Diagnostic Approach:** **1. Serum Beta-hCG (Quantitative):** A positive hCG confirms pregnancy. In an ectopic pregnancy, the hCG typically rises **more slowly than expected** for a viable intrauterine pregnancy. The "discriminatory zone" is the hCG level above which an intrauterine gestational sac should be visible on transvaginal ultrasound (usually 1,500–2,500 mIU/mL). If hCG exceeds the discriminatory zone but no intrauterine sac is seen, ectopic pregnancy is strongly suspected. **2. Serial Beta-hCG (every 48 hours):** In a viable intrauterine pregnancy, hCG doubles every 48–72 hours. In an ectopic pregnancy, the hCG rises **more slowly**, increases abnormally (rises by <53%), or plateaus. Conversely, a rising hCG with an empty uterus on ultrasound is diagnostic for ectopic pregnancy. **3. Transvaginal Ultrasound:** This is the gold standard for diagnosis. Findings include: - **Empty uterus** (no intrauterine gestational sac) - **Adnexal mass** (the ectopic pregnancy, often 1–3 cm) - **Free fluid in the pelvis** (suggests rupture and bleeding) - **No fetal cardiac activity** (in very early ectopic pregnancies, cardiac motion may not yet be present) **4. Culdocentesis (if diagnosis remains unclear):** A needle is inserted into the cul-de-sac (pouch of Douglas) through the posterior vaginal wall to aspirate fluid. If non-clotting blood is returned, intra-abdominal bleeding is confirmed (ruptured ectopic pregnancy). This test is now rarely used because transvaginal ultrasound is more sensitive and less invasive. **Management Approach:** **Option 1: Unruptured Ectopic Pregnancy with Hemodynamic Stability—Medical Management with Methotrexate:** **Indications:** - Hemodynamically stable patient (normal vital signs, no shock) - Unruptured tubal pregnancy confirmed on ultrasound - Ectopic mass <3.5–4 cm - No free fluid or minimal free fluid - Beta-hCG <5,000 mIU/mL (some protocols allow up to 10,000) - No contraindications to methotrexate - Patient reliable for follow-up **Methotrexate Pharmacology:** **Action**: Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase, blocking DNA synthesis. Rapidly dividing cells (trophoblast) are selectively killed, causing placental tissue to disintegrate and be reabsorbed. **Dosing**: - **Single-dose regimen**: 50 mg/m² IM (body surface area calculated from height and weight) - **Two-dose regimen**: 1 mg/kg/day IM on days 0 and 2, with folinic acid (leucovorin) rescue 0.1 mg/kg/day on days 1 and 3 - **Multiple-dose regimen** (least common): alternating methotrexate and folinic acid for 4–7 days The **single-dose regimen** is most commonly used; it has similar efficacy to multi-dose regimens and better tolerability. **Nursing Considerations for Methotrexate Administration:** 1. **Verify baseline labs**: CBC, liver function tests (AST, ALT, albumin), renal function (creatinine, BUN), and platelet count—methotrexate is hepatotoxic and nephrotoxic 2. **Ensure **not pregnant with intrauterine pregnancy** — ultrasound confirmation is mandatory 3. **Confirm Rh status**: if Rh-negative, administer Rho(D) immune globulin 4. **Administer IM** into deltoid or gluteal muscle; never IV (risk of toxicity) 5. **Monitor for toxicity**: bone marrow suppression (leukopenia, thrombocytopenia), hepatotoxicity, nephrotoxicity, mucositis **Patient Teaching for Methotrexate:** - **Folic acid**: AVOID folic acid supplements and high-folate foods (spinach, leafy greens, legumes) for 3 months—folic acid antagonizes methotrexate and reduces efficacy - **Alcohol**: AVOID alcohol completely; methotrexate + alcohol increases hepatotoxicity - **Sun exposure**: AVOID direct sun; methotrexate increases photosensitivity; use broad-spectrum SPF 50+ sunscreen - **Intercourse**: AVOID for 3 months (or at least until hCG is negative)—teratogenic if breakthrough pregnancy occurs - **NSAIDs**: AVOID (increase methotrexate toxicity); use acetaminophen for pain - **Lactation**: AVOID breastfeeding; methotrexate is excreted in breast milk - **Gastrointestinal symptoms**: nausea, vomiting, diarrhea, mouth sores are common; report severe symptoms **Follow-up After Methotrexate:** - **Beta-hCG on day 4 and day 7**: hCG should fall by ≥15% between days 4 and 7, confirming efficacy - **Weekly hCG** until negative (usually 4–6 weeks) - **Ultrasound**: repeat in 4–6 weeks to confirm resolution of adnexal mass - **Contraception**: mandatory for 3 months (methotrexate is highly teratogenic) **Success Rate:** Approximately 88–96% of appropriately selected ectopic pregnancies resolve with single-dose methotrexate. **Option 2: Ruptured Ectopic Pregnancy or Hemodynamic Instability—Emergency Surgical Management:** **Indications:** - Hemodynamic instability (tachycardia >110 bpm, hypotension, severe pain, syncope) - Ruptured ectopic pregnancy confirmed on imaging (free fluid in pelvis, absent heart rate in adnexal mass) - Acute abdomen with peritoneal irritation - Failed medical management (hCG plateau or rise after methotrexate) - Patient unreliable for close follow-up - Beta-hCG >10,000 mIU/mL (higher risk of rupture) **Surgical Options:** - **Salpingostomy**: incision in the tubal wall; the ectopic pregnancy is removed; the tube is left in place to preserve fertility - **Salpingectomy**: removal of the entire affected fallopian tube (often performed if massive hemorrhage or severe tube damage) - **Laparoscopy** vs. **laparotomy**: laparoscopy is preferred if patient is stable; laparotomy if massive hemorrhage or difficult anatomy **Priority Nursing Care for Ruptured Ectopic Pregnancy (Obstetric Emergency):** **1. Recognize & Activate Emergency Protocol:** - Triage immediately; recognize the **Kehr sign (shoulder pain) as a red flag** for intra-abdominal bleeding - Call obstetrician and anesthesiologist stat; alert operating room for emergency surgery - Activate massive transfusion protocol if available in your facility **2. Establish Hemodynamic Support:** - **Two or more large-bore IV lines** (16-gauge or larger); consider central line for rapid volume resuscitation - **Type and crossmatch** for multiple units of packed red blood cells (minimum 4 units) - **Initiate rapid fluid bolus**: 1–2 liters of normal saline or lactated Ringer's IV over 15–30 minutes - **Administer supplemental oxygen** via non-rebreather mask at 10–15 L/min (target SpO2 >95%) - **Continuous cardiac monitoring** and pulse oximetry - **Foley catheter** for urine output monitoring; target >30 mL/hr - **Monitor vital signs** every 5–15 minutes; anticipate further deterioration **3. Prepare for Emergency Surgery:** - **NPO status** (nothing by mouth); do not delay surgery for NPO time in emergency - **Informed consent**: obtain verbal consent if patient unstable; document in chart - **Preoperative labs**: CBC, comprehensive metabolic panel, PT/aPTT, blood type and crossmatch, beta-hCG - **Physical assessment**: document abdominal findings, pain level, vital signs, and mental status - **Notify anesthesia** of blood loss, hemodynamic status, and vital signs - **Ensure accurate count** of all sponges and instruments before closure - **Send tissue** for pathologic confirmation **4. Administer Rho(D) Immune Globulin:** - Give **300 mcg IM** (standard dose; microdose is not sufficient after rupture because significant fetal-maternal hemorrhage occurs) - Draw **Kleihauer-Betke test** (detects fetal red blood cells in maternal circulation) to quantify fetomaternal hemorrhage; if >15 mL fetal RBCs (or >4 mL fetal RBCs), additional Rho(D) immune globulin is needed (300 mcg per 4 mL fetal RBCs) **5. Provide Emotional Support:** - Explain what is happening in simple language; reassure the patient - Involve partner or family member if possible - After stabilization and surgery, allow time for processing the loss and the emergency event **Discharge Teaching After Ectopic Pregnancy:** - Complete methotrexate course if medical management was used; continue serial hCG until negative - Reliable contraception for 3 months (if methotrexate) or until healed from surgery (if surgical management) - Return to normal activity gradually; avoid heavy lifting, strenuous exercise for 2–4 weeks post-surgery - Sexual intercourse: resume after medical provider approval (typically 1–2 weeks post-surgery) - Report immediately: fever, persistent or severe pain, syncope, heavy vaginal bleeding, or persistent nausea/vomiting - **Recurrence risk**: approximately 25% of women with one ectopic will have another; early ultrasound in next pregnancy is recommended - **Fertility**: most women achieve pregnancy after ectopic; however, those with salpingectomy and no remaining tube, or severe contralateral tubal damage, may benefit from assisted reproductive technology (ART)

Gestational trophoblastic disease (GTD) encompasses a spectrum of conditions arising from abnormal proliferation of placental trophoblastic tissue. The benign end is the hydatidiform mole (molar pregnancy); the malignant end is gestational choriocarcinoma. Understanding this disease is critical for NLE success because molar pregnancy presents early warning signs (preeclampsia before 20 weeks, excessively high hCG) that demand immediate recognition and long-term surveillance to prevent malignant transformation. **Epidemiology:** Hydatidiform mole occurs in 1 in 1,000–2,000 pregnancies in North America but is more common in Asia, Africa, and Latin America. Risk factors include maternal age extremes (<20 or >40 years), prior molar pregnancy (increases risk 100-fold for recurrence), and possibly nutritional deficiency. **Types of Molar Pregnancy:** **1. Complete (Classical) Mole:** A complete mole has NO fetal tissue; it represents abnormal proliferation of chorionic villi. Karyotype is **46,XX (70%)** or **46,XY (30%)**, with both sets of chromosomes derived from paternal DNA only (androgenesis). The maternal contribution is lost. This is the form that carries the highest risk of progressing to choriocarcinoma (15–20%). **2. Partial Mole:** A partial mole contains some fetal tissue (often abnormal) and some abnormal placental tissue. Karyotype is typically **69 chromosomes (triploid)**: an abnormal combination of maternal chromosomes (two sets, diploidy) plus one set from sperm (triploidy: 69,XXY; 69,XXX; or 69,XYY). The fetus is severely growth-restricted and malformed. Risk of malignant transformation is lower (~1–5%) than complete mole. **Pathophysiology:** In a complete mole, the embryo fails to develop; chorionic villi proliferate abnormally and become filled with fluid, forming grape-like vesicles. HCG production is excessive (sometimes 5–10 times higher than a normal pregnancy at the same gestational age), leading to clinical manifestations of extreme hormonal stimulation. In a partial mole, some fetal development occurs, but the fetus is severely abnormal and nonviable. **Clinical Manifestations:** **1. Uterus Larger Than Expected for Gestational Age:** The overgrowth of molar tissue causes rapid uterine enlargement. By ultrasound, the uterus appears disproportionately large. This is one of the key early warning signs. **2. Vaginal Bleeding:** - **Dark brown ("prune juice")** or bright-red bleeding starting in the first or second trimester - Passage of **grape-like vesicles** (pathognomonic for molar pregnancy) — patients often describe "bleeding tissue" - Bleeding can be heavy and lead to anemia **3. Excessively High Beta-hCG:** Beta-hCG levels are abnormally elevated—often 5–10 times higher than expected for gestational age. This provides a vital diagnostic clue and explains the severe hormonal symptoms that follow. **4. Hyperemesis Gravidarum (Severe Morning Sickness):** Due to excessively high hCG, many women with molar pregnancy experience profound nausea, vomiting, and inability to maintain oral intake. This can lead to dehydration, electrolyte abnormalities, and weight loss rather than weight gain. **5. Hyperthyroidism:** The hyperproduction of hCG stimulates the thyroid. Women may present with heat intolerance, tachycardia, tremor, and anxiety. Thyroid function tests show suppressed TSH and elevated free T4. **6. Preeclampsia BEFORE 20 Weeks—A RED FLAG:** This is a distinguishing feature. Preeclampsia typically occurs after 20 weeks of gestation; if a woman develops preeclampsia symptoms (hypertension ≥140/90 mmHg, proteinuria, headache, visual disturbances, right upper quadrant pain, or seizure) **before 20 weeks**, molar pregnancy must be suspected. The excessively high placental-derived substances (hCG, human placental lactogen) trigger vasospasm and endothelial dysfunction characteristic of preeclampsia. **7. Absent Fetal Heart Tones & No Fetal Movement:** Unlike a normal pregnancy, there is no fetal cardiac activity and no fetal movement. This absence of fetal well-being signs, combined with uterine enlargement, bleeding, and preeclampsia before 20 weeks, is diagnostic. **Diagnostic Approach:** **1. Serum Beta-hCG (Quantitative):** Levels are **markedly elevated** relative to gestational age. If hCG is unusually high for the stated dates, molar pregnancy should be considered. **2. Ultrasound (Transvaginal Preferred):** - **"Snowstorm" or "bunch of grapes" appearance**: mixed echogenicity with numerous small cystic spaces scattered throughout (representing fluid-filled vesicles) - **Bilateral theca lutein cysts** in the ovaries (result of excess hCG stimulation) - **NO fetal heart tones** in a complete mole; possibly fetal tissues (though severely abnormal) in a partial mole - **Uterus larger than dates** **3. Chest X-ray (if molar pregnancy is suspected):** To rule out metastatic choriocarcinoma, especially if hCG is very high **4. CBC & Metabolic Panel:** To assess hemoglobin (assess anemia from bleeding), electrolytes, liver and renal function **Clinical Distinction: Complete vs. Partial Mole** | Feature | Complete Mole | Partial Mole | |---------|---------------|-------------| | Fetal tissue | None | Some (abnormal) | | Karyotype | 46,XX or 46,XY (androgenesis) | 69,XXX / 69,XXY / 69,XYY (triploidy) | | Uterine size | Often large for dates | Usually appropriate | | Vaginal bleeding | Heavy, early | Moderate | | hCG level | Very high (5-10× normal) | Mildly elevated | | Preeclampsia before 20 wks | Common (10%) | Rare | | Malignant potential | High (15-20% choriocarcinoma) | Low (1-5%) | | Ultrasound | Snowstorm; no fetus | Fetal tissue present but abnormal | **Management:** **1. Evacuation of the Uterus:** Once molar pregnancy is diagnosed, the uterus must be evacuated to: - Remove the abnormal tissue - Stop ongoing bleeding and hyperemesis - Reduce the risk of gestational trophoblastic neoplasia **Method:** - **Suction curettage** under general or regional anesthesia (preferred method) - Manual evacuation followed by gentle curettage (sharp curettage must be gentle to avoid uterine perforation) - Oxytocin (Pitocin) infusion before evacuation to promote uterine contraction and reduce bleeding **2. Post-Evacuation Management:** After evacuation, the critical issue is **surveillance for malignant transformation**. **Serial Beta-hCG Monitoring:** - Draw beta-hCG **weekly until negative**, then **monthly for 6–12 months** (some protocols recommend 12 months for complete mole) - Beta-hCG should fall progressively to normal (negative) within **8–12 weeks** - If hCG plateaus or rises, this signals **gestational trophoblastic neoplasia (GTN)**, which requires chemotherapy (methotrexate) - A rising hCG from a **new intrauterine pregnancy** would mask evidence of malignant change; hence, contraception is **mandatory** **3. Contraception Mandatory for 1 Year:** Because a rising hCG from a new pregnancy would mask malignant hCG rise, **reliable contraception is essential for at least 1 year** (some protocols say until hCG is negative for 6–12 months, then pregnancy may be attempted). Contraceptive options include: - Hormonal contraceptives (pill, patch, ring): suppress ovulation and reduce hCG stimulation - IUD: highly effective, does not interfere with hCG monitoring - Barrier methods + spermicide **4. Management of Gestational Trophoblastic Neoplasia (if diagnosed):** If hCG plateaus or rises, further imaging and chemotherapy are indicated: - **Chest X-ray & pelvic ultrasound** to assess for metastatic disease - **Methotrexate chemotherapy**: 1 mg/kg IM every other day for 5 days, alternating with folinic acid rescue, repeated every 14 days based on hCG response - **Alternative chemotherapy** for metastatic disease: etoposide, dactinomycin, cyclophosphamide - **Hysterectomy** may be offered to older women who have completed childbearing (removes source of abnormal tissue) **Nursing Care for Molar Pregnancy:** **Pre-Evacuation:** 1. **Assess for preeclampsia**: vital signs (especially BP), urine dipstick for protein, reflexes (clonus for seizure risk) 2. **Monitor for hyperemesis**: assess fluid/electrolyte status, provide IV hydration if severe, antiemetics (ondansetron 4–8 mg IV/IM every 4–6 hours) 3. **Prepare for evacuation**: NPO status, explain procedure, provide emotional support 4. **Monitor fetal heart tones** (though unlikely to be present): establish baseline vital signs, establish IV access **Post-Evacuation:** 1. **Monitor for hemorrhage**: assess vaginal bleeding, uterine tenderness/tone, hemoglobin; maintain IV access initially 2. **Rho(D) immune globulin**: give to Rh-negative, unsensitized women (300 mcg IM if significant blood loss; otherwise, calculate dose based on Kleihauer-Betke) 3. **Teach importance of serial hCG follow-up**: explain that hCG should fall progressively over 8–12 weeks; any plateau or rise signals malignancy 4. **Contraception counseling**: stress that pregnancy MUST be avoided for at least 1 year; provide education on reliable methods 5. **Emotional support**: address grief (loss of pregnancy), anxiety (risk of cancer), and need for prolonged surveillance 6. **Report any rising hCG immediately**: this signals gestational trophoblastic neoplasia and need for chemotherapy **Discharge Teaching:** - Continue serial beta-hCG testing (weekly until negative, then monthly for 6–12 months); keep all appointments - Use reliable contraception for at least 1 year; backup methods recommended if hormonal contraceptive used - Avoid pregnancy until cleared by oncologist (when hCG has been negative for 6–12 months) - Report immediately: vaginal bleeding, passage of tissue, abdominal pain, or any sign of infection - If chemotherapy is needed (rising hCG), side effects include nausea, mouth sores, bone marrow suppression, and hair loss; support services available - Prognosis: if diagnosed early and treated, >95% cure rate; only ~1–5% of complete moles progress to choriocarcinoma if detected by hCG surveillance **Follow-up After Molar Pregnancy:** Once hCG is negative for 6–12 months and malignancy is excluded, women can attempt pregnancy. In the next pregnancy: - **Early ultrasound** (8–10 weeks) to confirm intrauterine pregnancy and rule out recurrent molar pregnancy (rare, ~1% recurrence) - Repeat molar pregnancy still possible but uncommon - Prognosis for future pregnancies is excellent

Third-trimester bleeding (after 20 weeks) is the classic territory for NLE questions because it separates two life-threatening conditions with opposite presentation patterns and management strategies. The **golden rule is: painless bright-red bleeding = placenta previa; painful dark-red bleeding with rigid uterus = abruptio placentae.** Both can rapidly progress to shock and fetal death if not recognized and managed urgently. The challenge for nurses is distinguishing these conditions quickly and knowing when to intervene surgically. **General Principles for Third-Trimester Bleeding:** 1. **NEVER perform a vaginal or rectal examination** until placenta previa is ruled out by ultrasound. A vaginal examination with low-lying placenta can perforate the placenta and cause catastrophic hemorrhage requiring emergent hysterectomy or massive transfusion. 2. **Establish hemodynamic support immediately**: two large-bore IVs, type and crossmatch, oxygen, continuous monitoring. 3. **Assess fetal well-being**: continuous electronic fetal monitoring; listen for fetal heart tones; assess fetal movement. 4. **Quantify blood loss**: count and weigh perineal pads; visual estimate of bleeding severity. 5. **Prepare for emergency delivery** if bleeding is severe or fetal distress develops. ## **PLACENTA PREVIA** **Definition:** The placenta implants in the lower uterine segment, either partially or completely covering the internal cervical os (opening). Previa prevents vaginal delivery because descent of the fetus would tear and lacerate the placenta, causing fetal bleeding and maternal hemorrhage. **Classification:** 1. **Total (Complete) Previa**: placenta completely covers the internal os; vaginal delivery is impossible 2. **Partial Previa**: placenta partially covers the os; vaginal delivery may be possible if bleeding is controlled 3. **Marginal Previa**: placental edge is at the margin of the os; may allow vaginal delivery if previa resolves with uterine growth 4. **Low-Lying Placenta**: placenta is in lower uterine segment but does not reach the os (within 2 cm); often resolves as uterus grows; may allow vaginal delivery if at least 2 cm from os **Risk Factors:** - **Multiparity** (most common—placenta implants lower in multiparous women whose endometrium is thinner) - Prior cesarean section or uterine curettage (scarred or thin endometrium) - Prior placenta previa (recurrence risk ~10%) - Advanced maternal age (>35 years) - Multiple gestation (twins/triplets; more placental mass, placenta may be lower) - Cocaine use (causes placental infarction and placental migration) - In vitro fertilization (IVF) - Maternal smoking **Manifestations:** **1. Painless, Bright-Red Vaginal Bleeding:** This is the hallmark. Bleeding may start as spotting and progress to heavy flow. Unlike threatened abortion (where bleeding is mild) or abruptio placentae (where bleeding is dark and painful), previa bleeding is: - **Painless**: no uterine cramping or pain - **Bright red**: fresh maternal blood (not old blood or tissue) - Often occurs after intercourse, vaginal examination, or spontaneously - Can be massive and lead to rapid shock **2. Uterus is Soft, Non-Tender, with Normal Tone:** On examination, the uterus is relaxed (not rigid or board-like as in abruption). The fundus is soft. There is no uterine contractions or increased tone. **3. Malpresentation (Breech, Transverse Lie):** Because the placenta is in the lower segment, it can block fetal descent into the pelvis. The fetus often remains in a non-vertex (non-head-down) position. On assessment, abdominal palpation may reveal a breech (buttocks in pelvis) or transverse lie (shoulders and head to sides). **4. No Fetal Distress Initially:** Unless bleeding is massive and acute, fetal heart rate patterns are usually normal initially. The fetus maintains good oxygenation as long as the placenta is perfused. **Diagnostic Approach:** **1. Transabdominal Ultrasound (Preferred in Third Trimester):** - Confirms placental location - Measures distance of placental edge from internal os - Visualizes amount of amniotic fluid - Assesses fetal biometrics and heart rate - Rules out other causes of bleeding (abruption, fetal anomalies) **Note on Vaginal Ultrasound**: A transvaginal ultrasound can be performed if previa is strongly suspected and transabdominal ultrasound is inconclusive, BUT it should be done cautiously to avoid contact with the lower placental edge. It is more accurate than transabdominal for assessing placental location, but the provider performs it, not the nurse. **2. Assessment During Bleeding Episode:** - Count and weigh pads to quantify blood loss - Fetal heart rate, contraction pattern (monitor for labor) - Vital signs; signs of shock (tachycardia, hypotension, cool skin) - Abdominal examination: assess for distension, tenderness **Management of Placenta Previa:** **Stable Patient (Preterm Gestation, No Active Bleeding):** 1. **Expectant (Conservative) Management:** The goal is to prolong the pregnancy as long as safely possible to allow fetal maturation. - **Hospitalization vs. Outpatient Management**: depends on frequency and severity of bleeding and proximity to delivery - **Admission to hospital** if bleeding is heavy or if patient lives far from the hospital - **Outpatient management** if bleeding is minimal, patient is reliable, and close follow-up is ensured - **Activity Restriction**: bed rest is traditionally recommended, though evidence for strict bed rest preventing bleeding is limited. Most providers recommend: - Avoid strenuous activity, heavy lifting, prolonged standing - Pelvic rest: **NO INTERCOURSE, douches, or tampons** (these can trigger bleeding) - Continue light household activities; complete bed rest not necessary for all patients - **Fetal Maturity**: if delivery is anticipated before 34 weeks, administer **betamethasone** to accelerate fetal lung maturity: - **Betamethasone 12 mg IM** once daily for 2 doses, 24 hours apart (total 24 mg) - Reduces neonatal respiratory distress syndrome (RDS) by ~50% - Reduces neonatal death and intraventricular hemorrhage - Most effective if given 24 hours to 7 days before delivery - Alternative: dexamethasone 6 mg IM every 12 hours × 4 doses - **Iron Supplementation**: due to ongoing or recurrent bleeding, anemia is common. Prescribe iron 325 mg ferrous sulfate PO daily (or 150 mg iron as alternate) to maintain hemoglobin and hematocrit. - **Rh Status**: if mother is Rh-negative and the fetus is Rh-positive (or status unknown), administer Rho(D) immune globulin (300 mcg IM) after each significant bleeding episode to prevent isoimmunization. 2. **Delivery Timing:** - **If previa is confirmed** (especially total previa), **planned cesarean delivery at 36–37 weeks** (once fetal lungs are mature) is safest to avoid spontaneous labor with active hemorrhage - **If previa is partial or marginal and bleeding has stopped**, vaginal delivery may be considered; however, most providers recommend cesarean to avoid emergency delivery with uncontrolled bleeding - **If labor begins** or **active bleeding occurs before 36 weeks**, proceed to cesarean delivery emergently **Active Bleeding (Acute Hemorrhage):** 1. **Establish Hemodynamic Support:** - Two large-bore IV lines; prepare for rapid fluid and blood product replacement - Type and crossmatch for multiple units of packed RBCs - Initiate normal saline or lactated Ringer's bolus (1–2 liters) if hypotensive - Oxygen via nasal cannula 2–3 L/min or non-rebreather if shock - Continuous cardiac monitoring and pulse oximetry - Foley catheter for urine output monitoring (target >30 mL/hr) 2. **Monitor Fetus:** - Continuous electronic fetal monitoring; assess heart rate, variability, decelerations - If fetal distress develops (late decelerations, loss of variability, bradycardia), prepare for emergency cesarean 3. **Prepare for Emergency Cesarean Delivery:** - Alert obstetrician and anesthesia immediately - NPO status (if not already NPO) - Prepare OR; notify blood bank for massive transfusion protocol - Obtain verbal consent if patient unstable - **Type and crossmatch for multiple units** (minimum 4–6 units PRBCs) - Consider fresh frozen plasma, platelets, cryoprecipitate for coagulopathy if massive transfusion occurs **Postpartum Hemorrhage Risk with Placenta Previa:** The lower uterine segment contracts poorly compared to the upper segment. Therefore, after delivery (especially if cesarean), the patient is at high risk for ongoing bleeding from the placental bed. Be prepared for: - Aggressive uterine massage - Oxytocin (Pitocin) infusion: 10 units IV bolus, then 10 units in 500 mL IV over 4–6 hours - Methylergonovine (Methergine) 0.2 mg IM (causes sustained uterine contraction; avoid if hypertensive) - Tranexamic acid (antifibrinolytic): 1 g IV over 10 minutes - Possible need for surgical interventions (B-Lynch suture, uterine artery embolization, or hysterectomy) if pharmacologic measures fail ## **ABRUPTIO PLACENTAE (Placental Abruption)** **Definition:** Premature separation of a normally implanted placenta from the uterine wall before delivery of the fetus, typically after 20 weeks of gestation. The separation tears placental blood vessels, causing bleeding into the intervillous space (between placenta and decidua) and sometimes into the myometrium (uterine muscle). **Risk Factors:** 1. **Maternal Hypertension** (the LEADING association): chronic hypertension, gestational hypertension, preeclampsia—accounts for ~40% of abruptions 2. **Maternal Cocaine Use**: causes acute vasoconstriction and placental infarction → abruption 3. **Trauma**: motor vehicle accident, intimate partner violence, falls, placental abruption during labor or delivery 4. **Short Umbilical Cord**: limits placental descent and causes tearing 5. **Smoking & Substance Abuse**: increase risk 6. **Prior Abruption**: recurrence risk ~10–15% 7. **Multiparity & Advanced Age**: increase baseline risk 8. **Rapid Decompression of Overdistended Uterus**: polyhydramnios (excessive amniotic fluid) that ruptures suddenly 9. **Preeclampsia**: especially severe preeclampsia **Pathophysiology:** Abruption causes rupture of spiral arteries in the placental bed. Bleeding occurs into the intervillous space, stripping the placenta away from the decidua (decidua is the lining of the uterus). The fetus loses placental surface area, reducing oxygenation and nutrient transfer. Additionally, thromboplastin (tissue factor) from the separating placenta enters the maternal circulation, triggering **disseminated intravascular coagulation (DIC)**—a consumptive coagulopathy that depletes clotting factors and causes life-threatening bleeding. **Classification by Severity:** 1. **Mild Abruption** (<10% placental separation): - Vaginal bleeding (dark red, scant to moderate) - Mild uterine tenderness and cramping - No fetal distress - Vital signs stable - Coagulation studies normal - Expectant management may be possible if preterm 2. **Moderate Abruption** (10–50% separation): - Moderate to heavy vaginal bleeding - Uterine tenderness, increased tone, possibly contractions - Fetal heart rate abnormalities (tachycardia, variable decelerations) - Maternal tachycardia, possible mild hypotension - Laboratory evidence of DIC (low platelets, elevated PT/aPTT, low fibrinogen) - Requires urgent delivery 3. **Severe (Concealed) Abruption** (>50% separation, often placental abruption with retained blood): - Heavy vaginal bleeding OR **concealed bleeding** (little external bleeding, but massive blood accumulation behind placenta) - **Board-like, rigid, tender uterus** (hallmark) - Severe abdominal pain, often accompanied by: - **Back pain** (blood accumulating in myometrium irritates the uterus) - **Shoulder pain** (if blood extends through uterine wall and irritates diaphragm—similar to Kehr sign in ectopic rupture) - Signs of **hypovolemic shock**: tachycardia (>120 bpm), severe hypotension, cool clammy skin, syncope - **Fetal distress or fetal death** (from placental insufficiency) - **DIC** in full effect: bleeding from gums, nose, IV sites; petechiae; hemoglobinuria - Massive hemorrhage may result in obstetric emergency (hemorrhagic shock, death if untreated) **Clinical Distinction: Key Differences from Previa** | Feature | Placenta Previa | Abruptio Placentae | |---------|-----------------|-------------------| | Bleeding character | Painless, bright-red | Painful, dark-red | | Uterine tone | Soft, non-tender | Rigid, board-like, tender | | Associated pain | None | Severe abdominal and/or back pain | | Vital signs | Initially stable | Often tachycardia, hypotension (shock) | | Fetal distress | Usually absent (unless massive bleed) | Often present | | Blood loss visibility | Correlates with external bleeding | May be concealed; external bleeding underestimates true loss | | DIC risk | Low | HIGH (thromboplastin enters circulation) | | Delivery method | Cesarean (preterm) or planned | EMERGENCY cesarean | **Manifestations of Abruptio Placentae:** **1. Vaginal Bleeding (Revealed or Concealed):** - **Revealed**: vaginal bleeding is dark red (old blood), often scanty, but may be heavy - **Concealed**: little to NO external bleeding, but blood accumulates behind the placenta within the uterus; external bleeding does not reflect the true amount of hemorrhage - **Couvelaire Uterus** (uteroplacental apoplexy): if bleeding extends into the myometrium (muscle layer), the uterus becomes infiltrated with blood, appearing bruised and ecchymotic. The uterus becomes rigid and may rupture spontaneously. **2. Severe Abdominal Pain:** - **Localized to the site of abruption** or generalized across the abdomen - **Back pain** is common if blood accumulates in the myometrium - Pain is often described as severe, sharp, or tearing - Often accompanied by **shoulder pain** (referred pain from diaphragmatic irritation if bleeding breaks through the uterine wall) **3. Uterine Findings: The Board-Like Rigid Uterus:** - **Increased uterine tone** (baseline tone at rest is elevated, normally 5–10 mmHg; in abruption, it may be 30+ mmHg) - **Uterine rigidity** (uterus feels like a hard board; cannot indent it with palpation) - **Uterine tenderness** and pain with palpation or contractions - Uterus may feel larger than expected (due to blood accumulation) - Contractions may be frequent and poorly coordinated (tetanic contractions) **4. Fetal Distress:** - **Tachycardia** (>160 bpm) initially as fetus compensates for reduced oxygenation - **Late decelerations** (decreased HR after uterine contractions, reflecting placental insufficiency) - **Variable decelerations** (if cord is compressed by blood clot) - **Loss of variability** (ominous sign of fetal hypoxia) - **Bradycardia** (<110 bpm for >2 minutes—sign of severe fetal hypoxia) - **Fetal demise** (if abruption is severe; fetus may have died before admission) **5. Maternal Signs of Shock (with Severe Abruption):** - **Tachycardia** (>100 bpm, often >120 bpm in severe cases) - **Hypotension** (systolic <90 mmHg—a LATE sign; compensated shock can exist with normal BP) - **Oliguria** (urine output <30 mL/hr or negligible; reflects poor perfusion) - **Cool, clammy, cyanotic skin**; pale mucous membranes - **Anxiety, restlessness, confusion** (altered mental status) - **Pulmonary edema** (if massive transfusion given) **6. Laboratory Evidence of DIC:** - **Thrombocytopenia** (platelets <100,000/μL; can drop to <10,000) - **Elevated PT/INR** (prolonged prothrombin time, reflecting Factor VII deficiency) - **Elevated aPTT** (prolonged partial thromboplastin time, reflecting deficiencies in intrinsic pathway factors) - **Low fibrinogen** (<100 mg/dL; normal is 200–400 mg/dL) - **Elevated D-dimer** (product of fibrin breakdown; very high in DIC) - **Schistocytes on peripheral smear** (fragmented RBCs from microangiopathic hemolytic anemia) - **Bleeding time** prolonged **Diagnostic Approach:** **1. Clinical Assessment (Most Important):** The diagnosis of significant abruption is often made clinically based on: - Painless bright-red bleeding = ruled out - Painful dark-red bleeding + rigid uterus + signs of shock = highly suggestive of abruption - **Ultrasound findings are SECONDARY** because abruption can be diagnosed clinically and ultrasound may be falsely reassuring (many abruptions are not clearly visible) **2. Ultrasound:** - Retroplacental clot (collection of blood behind placenta) - Placental abruption is most clearly visible if **subchorionic** (beneath the chorionic membrane, not buried in the myometrium) - Massive abruptions can appear as areas of heterogeneous echogenicity (mix of blood and clot) - **Absence of ultrasound findings does NOT rule out abruption** (especially if bleeding is concealed in myometrium) - Rules out previa and other causes **3. Laboratory Studies:** - **CBC**: baseline hemoglobin and hematocrit; monitor for drop with ongoing bleeding - **Coagulation panel**: PT, aPTT, fibrinogen, D-dimer to detect DIC - **Type and crossmatch**: for potential transfusion - **Kleihauer-Betke**: quantify fetomaternal hemorrhage (important for Rh-negative mothers) **4. Fetal Monitoring:** - **Continuous electronic fetal monitoring** (CTG) to assess fetal well-being and detect distress - **Fetal ultrasound** if viability is in question **Management of Abruptio Placentae:** **Mild Abruption (Preterm, No Fetal Distress, Stable Patient):** 1. **Expectant Management** (if <34 weeks and stable): - **Hospitalization** for close monitoring - **Bed rest** (strict activity restriction) - **Continuous fetal monitoring** (assess for worsening distress) - **Serial ultrasound** (assess placental status) - **Betamethasone** if delivery likely before 34 weeks (12 mg IM × 2 doses 24 hours apart) - **Transfusion** if hemoglobin drops significantly - **Rho(D) immune globulin** if Rh-negative - **Discharge if:** bleeding stops, no fetal distress, stable vital signs, reliable for follow-up - **Readmit immediately if:** bleeding resumes, fetal distress develops, or pain worsens **Moderate-to-Severe Abruption (Any Gestational Age) or Fetal Distress:** **EMERGENCY CESAREAN DELIVERY IS INDICATED.** 1. **Prepare for Emergency Surgery:** - **Activate obstetric emergency protocol**; notify obstetrician, anesthesia, blood bank, OR - **Two large-bore IV lines** (18-gauge or larger); prepare for massive transfusion - **Type and crossmatch** for minimum 4–6 units PRBCs; have FFP, platelets, cryoprecipitate available - **Continuous fetal and maternal monitoring** - **Foley catheter** for urine output monitoring (indicator of renal perfusion) - **NPO status**; if unstable, proceed to surgery regardless 2. **Initiate Hemodynamic Support:** - **Normal saline or lactated Ringer's** bolus 1–2 liters IV rapidly if signs of shock - **Supplemental oxygen** via nasal cannula or non-rebreather; target SpO2 >95% - **Elevate legs** to promote venous return (if not contraindicated) - **Keep warm** (prevent hypothermia from massive transfusion) 3. **Blood Product Management (Massive Transfusion Protocol):** - **Packed RBCs**: initial bolus 2–4 units; continue based on CBC and vital signs - **Fresh frozen plasma (FFP)**: 1 unit per unit of PRBCs (maintains coagulation factors) - **Platelets**: if platelet count <50,000 or ongoing microvascular bleeding - **Cryoprecipitate**: if fibrinogen <100 mg/dL (2–4 units to replenish fibrinogen) - **Tranexamic acid** (Cyklokapron) 1 g IV over 10 minutes; may reduce transfusion requirements and mortality in trauma/postpartum hemorrhage - **DIC management**: treat with fresh products, not just RBCs alone 4. **Cesarean Delivery:** - **Classic vertical (classical) cesarean incision** preferred over low transverse if massive hemorrhage anticipated (allows faster entry and better access to bleeding vessels) - After delivery, assess for: - **Couvelaire uterus** (bruised, infiltrated myometrium) - Massive blood loss from placental bed - If uterus cannot be controlled with massage and oxytocin, **hysterectomy** may be necessary - Deliver placenta and send for pathology - Control bleeding with uterotonic agents and, if needed, surgical hemostasis (B-Lynch brace suture, uterine artery ligation, or emergency hysterectomy) 5. **Intensive Postoperative Care:** - Monitor urine output closely (oliguria signals ongoing shock or acute kidney injury) - Serial hemoglobin/hematocrit - Coagulation studies (PT, aPTT, fibrinogen, D-dimer, platelets) - Watch for **acute respiratory distress syndrome (ARDS)** from massive transfusion - Monitor for DIC: bleeding from gums, nose, IV sites; petechiae; hematuria - Aggressive fever management and infection prevention - Pain control; psychological support **Rho(D) Immune Globulin:** - If mother is Rh-negative, unsensitized, and fetus is Rh-positive: - Administer **300 mcg IM** after abruption (standard dose for significant fetomaternal hemorrhage) - **Kleihauer-Betke** or **flow cytometry** to quantify fetal RBCs; if >4 mL fetal RBCs (or >15 mL fetal whole blood), additional Rho(D) immune globulin is needed (300 mcg per 4 mL fetal RBCs) - Document lot number and expiration **Discharge Teaching (for Mild Abruption Managed Expectantly):** - Return immediately if vaginal bleeding resumes, pain worsens, or any signs of labor - Continue bed rest; pelvic rest (no intercourse) - Avoid strenuous activity, lifting, prolonged standing - Attend all follow-up appointments; repeat ultrasound as scheduled - **Report immediately**: heavy vaginal bleeding, severe abdominal or back pain, shoulder pain, dizziness/fainting, contractions, or decreased fetal movement

Rho(D) immune globulin (RhoGAM, Rhophylac) is a cornerstone medication in obstetrics that every nurse must understand cold for the NLE. Its purpose is preventing **Rh isoimmunization** (sensitization) in an **Rh-negative mother**, protecting not only the current pregnancy but all future pregnancies from the devastating consequences of hemolytic disease of the newborn (HDN). Understanding when to give it, how to give it, eligibility criteria, and post-administration counseling is essential for safe obstetric practice. **The Rh Antigen System: Brief Immunology Review:** The Rh antigen is a red blood cell surface antigen. People are either: - **Rh-positive** (have the D antigen; ~85% of population) - **Rh-negative** (lack the D antigen; ~15% of population) Rh status is genetically inherited and does not change during pregnancy. **The Problem: Rh Sensitization:** If an **Rh-negative mother** is exposed to **Rh-positive fetal blood** (fetomaternal hemorrhage—FMH), her immune system recognizes the Rh antigen as "foreign" and mounts a **primary immune response**, creating IgM antibodies initially, then IgG antibodies (after 6–8 weeks). These IgG antibodies are small enough to cross the placenta. In a **subsequent Rh-positive pregnancy**, maternal IgG antibodies cross the placenta, attack fetal RBCs bearing the Rh antigen, cause hemolysis (destruction), and result in: - **Fetal anemia** (from RBC destruction) - **Fetal hydrops** (severe edema; fluid in lungs, abdomen, heart sac) - **Kernicterus** (bilirubin brain damage in the newborn) - **Fetal death** (if severe) This is **hemolytic disease of the newborn (HDN)**, a devastating preventable condition. **Prevention with Rho(D) Immune Globulin:** Rho(D) immune globulin is a **passively administered human polyclonal antibody** (contains IgG anti-D) that: 1. **Coats the Rh-positive fetal RBCs** exposed to maternal circulation 2. **Prevents the mother's immune system from recognizing them as foreign** (they are now coated with maternal IgG) 3. **RBCs are destroyed in the spleen** before the mother's own immune response kicks in 4. **Prevents primary sensitization** (primary immune response is averted) 5. **Protects future pregnancies** (mother never becomes sensitized; no IgG anti-D produced by mother's own immune system) It is **passive immunity**—Rho(D) immune globulin provides antibodies; it does not stimulate the mother to produce her own antibodies. **Dosing & Administration:** **Standard Dose: 300 mcg (1,500 IU) IM** - **Timing**: within **72 hours** of delivery of an Rh-positive infant (can be given anytime before 28 days postpartum, but efficacy declines over time) - **Route**: **intramuscular only**; usually into the deltoid (upper arm) or gluteus maximus (buttock); never IV (risk of toxicity) - **Also given at 28 weeks gestation** as routine antepartum prophylaxis (even if no bleeding event) **Microdose: 50 mcg (250 IU) IM** - **Indication**: for **first-trimester events** (before 13 weeks): spontaneous or induced abortion, ectopic pregnancy, molar pregnancy, therapeutic abortion/termination at <13 weeks - **Rationale**: fetomaternal hemorrhage is minimal in first trimester, so smaller dose (50 mcg) covers the typical ~0.5 mL fetal RBCs - **If uncertain whether microdose is adequate**: can draw **Kleihauer-Betke test** to quantify fetal RBCs; if >0.5 mL fetal RBCs, give additional 300 mcg for each additional 4 mL fetal RBCs **Full Dose: 300 mcg IM** - **Indications**: - **Delivery of an Rh-positive infant** (within 72 hours postpartum) - **Placental abruption** (significant fetal-maternal hemorrhage) - **Ectopic pregnancy rupture** (second or third trimester; if first trimester, microdose may suffice) - **Amniocentesis or chorionic villus sampling (CVS)** - **Abdominal trauma** (motor vehicle accident, intimate partner violence) - **Intrauterine fetal death** (if Rh-positive fetus) - **Molar pregnancy** (if significant bleeding) - **Any vaginal bleeding in third trimester** (if previa, abruption, or other cause with potential significant FMH) - **Routine antepartum prophylaxis at 28 weeks** (standard dose) **Calculating Additional Dose for Massive FMH:** If fetomaternal hemorrhage is quantified as >4 mL fetal RBCs (or >15 mL fetal whole blood), additional Rho(D) immune globulin is needed: **Formula**: - **300 mcg Rho(D) immune globulin covers ~4 mL of fetal RBCs** (or ~15 mL fetal whole blood) - **Additional dose = (Number of mL fetal RBCs / 4) × 300 mcg** **Example**: If Kleihauer-Betke shows 12 mL fetal RBCs: - (12 mL / 4 mL) × 300 mcg = 3 × 300 mcg = 900 mcg (3 vials) needed **Eligibility Criteria: Who Gets Rho(D) Immune Globulin?** **MOTHER must be:** 1. **Rh-negative** (confirmed by blood type) 2. **Direct Coombs negative** (her RBCs are not already coated with antibodies; indicates she is not sensitized to Rh antigen) 3. **Indirect Coombs negative** (her serum does not contain anti-D antibodies; she is unsensitized) **FETUS or NEWBORN must be:** 1. **Rh-positive** (or status unknown—give Rho(D) immune globulin "just in case") 2. **Direct Coombs negative** (no hemolysis yet) **If mother is already sensitized (IgG anti-D positive):** - Rho(D) immune globulin will NOT prevent hemolytic disease - Continue with close monitoring; if third-trimester or newborn HDN develops, manage with intrauterine transfusion, phototherapy, exchange transfusion as needed **Nursing Responsibilities for Rho(D) Immune Globulin Administration:** **Before Administration:** 1. **Verify Rh status** of mother and baby (or fetus) 2. **Check indirect Coombs result** for mother (should be negative for unsensitized) 3. **Check direct Coombs result** for baby (should be negative) 4. **Verify dose** on the vial matches provider order (usually 300 mcg for postpartum or ≥13 weeks events; 50 mcg for first-trimester events) 5. **Check expiration date** and lot number 6. **Inspect vial** for discoloration or particulate matter (should be clear or slightly opalescent) 7. **Document lot number in chart** (for potential adverse event tracking) 8. **Obtain informed consent** if possible; explain that injection protects future babies from blood type incompatibility problems **During Administration:** 1. **Route**: **IM only** (never IV; can cause hemoglobinuria, renal failure) 2. **Site**: deltoid muscle (upper arm) or gluteus maximus (buttock); rotate sites if multiple doses 3. **Technique**: use sterile needle (25-gauge or smaller), cleanse skin with alcohol, inject into muscle 4. **Document**: site of injection, lot number, expiration date, and batch number in chart **After Administration:** 1. **Monitor for adverse effects**: - **Fever**: mild fever (99–101°F / 37.2–38.3°C) is common; acetaminophen may be given - **Injection site reactions**: local pain, redness, swelling (usually minor, resolve in hours) - **Chills, malaise**: uncommon but possible - **Anaphylaxis** (rare but possible, especially in patients with IgA deficiency): watch for urticaria, wheezing, hypotension, stridor 2. **Rest period**: allow 15–20 minutes for observation if first time receiving Rho(D) immune globulin 3. **Educate the patient**: - Explain that the injection protects future babies - Advise that mild fever or local reactions are normal - Advise to report severe reactions (anaphylaxis) - Counsel to inform future providers of Rh-negative status and need for Rho(D) immune globulin **Patient Teaching: Rho(D) Immune Globulin** "This injection protects your future pregnancies. Your blood type is Rh-negative, which means your RBCs lack a certain antigen. If your baby is Rh-positive (has that antigen), and your baby's blood mixes with yours, your body could develop antibodies against that antigen. In future pregnancies, these antibodies would attack your baby's RBCs and cause serious disease. This injection contains antibodies that prevent your body from making its own antibodies, so your future babies will be protected. We are giving it to you now (and again if you have bleeding events or deliver an Rh-positive baby) to keep you and your future children safe." **Documentation in Chart:** - **Rho(D) immune globulin 300 mcg IM (or 50 mcg)** administered - **Site**: left deltoid or right gluteus maximus - **Lot number**: [enter] - **Expiration date**: [enter] - **Indication**: postpartum prophylaxis after delivery of Rh-positive infant (or antepartum prophylaxis at 28 weeks, or event-based: abruption, ectopic rupture, trauma, abortion, etc.) - **Kleihauer-Betke result**: [if performed] - **Additional doses given (if FMH quantified as >4 mL fetal RBCs)**: [enter if applicable] - **Patient education**: explained protective role of Rho(D) immune globulin; advised to inform future providers of Rh-negative status - **Signature & credentials**: RN initials, credentials **Timing: Critical for Efficacy** **The "72-Hour Window":** - **Maximum efficacy**: if Rho(D) immune globulin is given **within 72 hours** of delivery/event - **Diminished efficacy**: if given **after 72 hours**; can still be given up to **28 days postpartum**, but protection is less reliable - **Lesson for NLE**: emphasize that prompt administration (within 72 hours) is crucial; do not delay **Postpartum Protocol in Philippine Healthcare Settings:** In Philippine hospitals and rural health units, Rho(D) immune globulin administration after delivery should be: 1. **Identified before discharge**: check mother's Rh status and baby's Rh (if known) 2. **Given before mother leaves hospital** if mother is Rh-negative, unsensitized, and baby is Rh-positive 3. **If baby's status is unknown at discharge**: mother should return within 72 hours for administration once baby's Rh is confirmed 4. **Document clearly** that Rho(D) immune globulin was or was not given (and reason) 5. **Counsel mother** to inform future providers of her Rh-negative status **Common NLE-Style Questions:** 1. **"A 28-year-old Rh-negative, unsensitized woman at 8 weeks has an incomplete abortion. What is the appropriate Rho(D) immune globulin dose?"** - **Answer**: 50 mcg (microdose) IM, because abortion occurred in first trimester (<13 weeks), when fetomaternal hemorrhage is minimal. 2. **"An Rh-negative primigravida delivers an Rh-positive infant. The Kleihauer-Betke test shows 3 mL fetal RBCs. How much Rho(D) immune globulin should be given?"** - **Answer**: 300 mcg (standard dose) IM, because 3 mL fetal RBCs is <4 mL, which is covered by the standard 300 mcg dose. 3. **"An Rh-negative woman with placental abruption at 32 weeks has a Kleihauer-Betke result of 20 mL fetal RBCs. What is the total Rho(D) immune globulin dose?"** - **Answer**: (20 mL / 4 mL) × 300 mcg = 5 × 300 mcg = 1,500 mcg (5 vials) IM. 4. **"An Rh-negative woman, indirect Coombs positive, delivers an Rh-positive infant. Should Rho(D) immune globulin be given?"** - **Answer**: NO, because the mother is already sensitized (positive indirect Coombs = she already has IgG anti-D antibodies). Rho(D) immune globulin will not prevent hemolytic disease; monitoring for fetal/neonatal hemolytic disease is needed instead.